Drug Profile
Anti-Mucin1 chimeric antigen receptor T cell therapy - PersonGen Biomedicine
Alternative Names: anti-MUC1 CAR T Cells; anti-MUC1-CAR transduced autologous T cells; Anti-Mucin1 (MUC1) CART cell therapy - PersonGen Biomedicine; Anti-Mucin1 CART cells; Anti-Mucin1 specific CART cellsLatest Information Update: 11 Oct 2021
Price :
$50
*
At a glance
- Originator PersonGen Biomedicine
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 11 Oct 2021 Discontinued - Phase-I/II for Solid tumours (Late-stage disease, Second-line therapy or greater) in China (Parenteral)
- 05 Sep 2018 Phase-I/II development is ongoing in China (NCT02617134) (NCT02587689)
- 11 Jul 2016 PersonGen Biomedicine reinitiates enrolment in two phase I/II trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in China (NCT02587689) (NCT02617134)